Location: San Antonio, United States
Date: December 6 to December 10
San Antonio Breast Cancer Symposium.
PrECOG 0102: A Randomized, Double-Blind Phase II Trial of Fulvestrant plus Everolimus or Placebo in Post-Menopausal Women with Hormone-Receptor Positive, HER2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
A Randomized, Double-blinded, Placebo-controlled Clinical Trial: Results from NRG Oncology/NSABP B-42
Efficacy and tolerability of veliparib in combination; Phase 2 Study
Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer (MBC)
Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cance
Adjuvant Ibandronate in early breast cancer First results of the TEAM Iib trial
Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive Breast Cancer treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Concurrent Estrogen Deprivation Thera
Aromatase inhibitors and endothelial function: is there an association with early cardiovascular disease?
Menopausal symptoms as predictors of long-term adherence in the International Breast Cancer Intervention Study (IBIS-1)
Double-blind Concordance Study of Breast Cancer Treatment, Recommendations Between Manipal Multidisciplinary Tumor Board and an Artificial Intelligence Advisor for Oncology, IBM’s Watson For Oncology
Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenop. patients with HR+, HER2- breast cancerBiological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenop. patients with HR+, HER2- breast
Breast cancer initiative 2.5 (BCI2.5): A framework for systematic improvement in global breast cancer outcomes
Treatment of metastatic breast cancer in older adults
Highglights of the congress (Extended studies)
IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy
Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial
Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study
Breast cancer health disparities. Women from different ethnic groups: Biology vs. other factors.
Advances in metastatic breast cancer with Cdk 4/6 inhibitors, PI3 inhibitors
hase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)